Skip to main content

Rybelsus News

GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression

MONDAY, May 19, 2025 – For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric...

GLP-1 Weight Loss Drugs Cut Alcohol Cravings By Two-Thirds

TUESDAY, May 13, 2025 — Cutting-edge weight-loss drugs like Ozempic/Wegovy can cut alcohol intake dramatically in a short amount of time, a new study says. People taking semaglutide or liraglutide r...

GLP-1 Receptor Agonists Reduce Alcohol Intake in Patients Treated for Obesity

MONDAY, May 12, 2025 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research letter recently published in Diabetes, Obesity and...

Semaglutide Beneficial in Metabolic Dysfunction-Associated Steatohepatitis, Fibrosis

FRIDAY, May 2, 2025 – For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes, according to a study...

Adverse Events From Semaglutide Seen in the ED Usually GI-Related

TUESDAY, April 15, 2025 – The rate of emergency department visits for adverse events among patients dispensed semaglutide is low, with most visits involving gastrointestinal effects, according to a...

Tirzepatide Dispensations Increased Rapidly After Approval

TUESDAY, April 15, 2025 – After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without...

Semaglutide Ups Risk for Nonarteritic Anterior Ischemic Optic Neuropathy in Diabetes

TUESDAY, April 8, 2025 – For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION), according to a study published...

ACC: Semaglutide Beneficial in Patients With T2DM and Peripheral Artery Disease

WEDNESDAY, April 2, 2025 – For patients with symptomatic peripheral artery disease and type 2 diabetes, semaglutide use is associated with increased walking distance, according to a study published...

Tirzepatide, Semaglutide Not Cost-Effective at Current Prices

WEDNESDAY, March 19, 2025 – Tirzepatide and semaglutide offer long-term health benefits but are not cost-effective, according to a study published online March 14 in JAMA Health Forum. Jennifer H....

GLP-1 RA Use Tied to Better Kidney Transplant Outcomes in Patients With Diabetes

TUESDAY, March 18, 2025 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to...

No Weight Loss Benefit Seen for Neoadjuvant Semaglutide Before Weight Loss Surgery

WEDNESDAY, March 12, 2025 – Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss, according to a research letter published online March 5 in...

Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM

MONDAY, March 10, 2025 – For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers...

No Link Seen Between Preop GLP-1 Receptor Agonist Use and Postop Aspiration Pneumonia

THURSDAY, March 6, 2025 – Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative aspiration pneumonia, according to a study published...

Obesity On The Rise Worldwide, Report Says

TUESDAY, March 4, 2025 – More than half of adults and a third of children and teens worldwide will be overweight or obese by 2050, a comprehensive global analysis has concluded. Overweight and...

GLP-1 Receptor Agonist Use Not Linked to Increased Suicide Risk

MONDAY, March 3, 2025 – Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Diabetes, Type 2

Rybelsus patient information at Drugs.com